Cas:147118-37-4 N-[4-(4-Fluorophenyl)-5-formyl-6-(1-methylethyl)-2-pyrimidinyl]-N-methyl-methanesulfonamide manufacturer & supplier

We serve Chemical Name:N-[4-(4-Fluorophenyl)-5-formyl-6-(1-methylethyl)-2-pyrimidinyl]-N-methyl-methanesulfonamide CAS:147118-37-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

N-[4-(4-Fluorophenyl)-5-formyl-6-(1-methylethyl)-2-pyrimidinyl]-N-methyl-methanesulfonamide

Chemical Name:N-[4-(4-Fluorophenyl)-5-formyl-6-(1-methylethyl)-2-pyrimidinyl]-N-methyl-methanesulfonamide
CAS.NO:147118-37-4
Synonyms:4-(4-Fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulphonylamino)pyrmidine-5-carboxaldehyde;N-[4-(4-fluorophenyl)-5-formyl-6-(propan-2-yl)pyrimidin-2-yl]-N-methylmethanesulfonamide;4-(4-Fluorophenyl)-6-isopropyl-2-(N-methyl-N-methanesulfonylamino)-5-pyrimidinecarboxaldehyde;Methanesulfonamide, N-[4-(4-fluorophenyl)-5-formyl-6-(1-methylethyl)-2-pyrimidinyl]-N-methyl-;N-[4-(4-Fluorophenyl)-5-formyl-6-isopropylpyrimidin-2-yl]-N-methylmethanesulfonamide;N-[4-(4-Fluorophenyl)-5-formyl-6-isopropyl-2-pyrimidinyl]-N-methylmethanesulfonamide;MFCD08458342;INTERMEDIATE OF ROSUVASTATIN;4-(4-Fluorophenyl)-6-isopropyl-2-[(N-methyl-N-methylsulfonyl)amino]pyrimidinyl-5-yl-formyl;4-(4-FLUOROPHENYL)-6-ISOPROPYL-5-FORMYL-2 (N-METHYL-N-METHANESULFONYLAMINO) PYRIMIDINE
Molecular Formula:C16H18FN3O3S
Molecular Weight:351.396
HS Code:2935009090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:536.6±60.0 °C at 760 mmHg
Density:1.3±0.1 g/cm3
Index of Refraction:1.575
PSA:88.61000
Exact Mass:351.105286
LogP:1.03

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 4-(4-Fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulphonylamino)pyrmidine-5-carboxaldehyde chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-(4-FLUOROPHENYL)-6-ISOPROPYL-5-FORMYL-2 (N-METHYL-N-METHANESULFONYLAMINO) PYRIMIDINE physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-(4-Fluorophenyl)-6-isopropyl-2-(N-methyl-N-methanesulfonylamino)-5-pyrimidinecarboxaldehyde Use and application,4-(4-FLUOROPHENYL)-6-ISOPROPYL-5-FORMYL-2 (N-METHYL-N-METHANESULFONYLAMINO) PYRIMIDINE technical grade,usp/ep/jp grade.


Related News: Beta Bionics is a for-profit Massachusetts public benefit corporation founded in 2015 to commercialize the iLet, a revolutionary bionic pancreas that is driven by mathematical dosing algorithms, which incorporate lifelong autonomous learning to automatically control glycemia. N-[4-(4-Fluorophenyl)-5-formyl-6-(1-methylethyl)-2-pyrimidinyl]-N-methyl-methanesulfonamide manufacturer Amanpour is based in London, and said she feels fortunate to have health insurance through work and incredible doctors who are treating me in a country underpinned by, of course, the brilliant NHS [National Health Service],” CNN reported.
“I want to applaud Christiane Amanpour for her candor, bravery and always working towards the greater good,” he said in a statement. “As a cancer survivor, I too encourage people to listen to their bodies and get all early cancer screenings available to them. N-[4-(4-Fluorophenyl)-5-formyl-6-(1-methylethyl)-2-pyrimidinyl]-N-methyl-methanesulfonamide supplier Among 30,000 volunteers — all of them from either the United States or Mexico — vaccinated people were completely protected against severe and even moderate cases of illness. N-[4-(4-Fluorophenyl)-5-formyl-6-(1-methylethyl)-2-pyrimidinyl]-N-methyl-methanesulfonamide vendor Beta Bionics is a for-profit Massachusetts public benefit corporation founded in 2015 to commercialize the iLet, a revolutionary bionic pancreas that is driven by mathematical dosing algorithms, which incorporate lifelong autonomous learning to automatically control glycemia. N-[4-(4-Fluorophenyl)-5-formyl-6-(1-methylethyl)-2-pyrimidinyl]-N-methyl-methanesulfonamide factory In recent years, there has been a relatively concentrated concentration of intermediate companies listed on the capital market. Most of the fund-raising projects are aimed at breaking through the bottleneck of production capacity to meet growing demand, and the entire industry has shown a vigorous development momentum.